Primary Cutaneous Melanoma Pathology Reporting Proforma

Includes the ICCR International Collaboration on Cancer reporting dataset denoted by *

Family name

Given name(s)

Date of birth

DD – MM – YYYY

Sex

- ☐ Male
- ☐ Female
- ☐ Intersex/indeterminate

Ethnicity

- ☐ Unknown
- ☐ Aboriginal/Torres Strait Islander
- ☐ Other ethnicity:

Patient identifiers
e.g. MRN, IHI or NHI (please indicate which)

Date of request

DD – MM – YYYY

S1.03 Accession number

Requesting doctor - name and contact details

***Tumour site**

Not provided ◯ Specify ▼

***Specimen laterality**

Left ◯ Right ◯ Midline ◯ Not provided ◯

Clinical or differential diagnosis

***Specimen type**

Not provided ◯ Curette ◯
Excision ◯ Shave ◯
Punch ◯ Re-excision ◯ ▶ complete details below
Incision ◯ Other ◯ ▼

If re-excision:

Previous laboratory

Previous lab accession number

Findings in previous biopsy

History & timing of lesional trauma, biopsy, irritation or treatment with topical agent

Past history of melanoma?

No ◯
Yes ◯ ▶ Details eg site, thickness, timing, treatment

Evidence of metastatic disease?

No ◯
Yes ◯ ▶ Describe (and consider recording serum LDH below):

Serum lactate dehydrogenase

I.U.

Other relevant history

Details of specimen orientation

Any clinically or dermatoscopically identified suspicious areas?

No ◯

Yes ◯ Describe:

Clinical or other relevant diagnostic imaging results

New primary melanoma or recurrence

New primary ◯

Recurrence – local ◯

Recurrence – intransit metastasis (between primary site and regional node field) ◯

Recurrence – regional ◯

Recurrence – distant ◯

Not stated ◯

S1.04 Principal clinician caring for the patient

G1.01 Other clinical information received

Macroscopic findings

G2.01 *Specimen description

G2.03 *Specimen dimensions

length mm x width mm x depth mm

G2.04 *Specimen orientation

(This refers to the information received from the surgeon regarding orientation of the specimen by marking sutures, clips or other techniques)

Not provided ◯ Specify (if known)

G2.05 *Macroscopic primary lesion description

(The description of the lesion includes includes such features as shape, colour, border, contour, evidence of surface crusting or ulceration and proximity to resection margins)

G2.06 *Macroscopic primary lesion dimensions

length mm x width mm x depth mm

Indeterminate ◯ (Note: Depth is optional)

G2.07 *Other lesion(s)

Not identified ◯ Present ◯

*Macroscopic description of other lesion(s)

(The description of the lesion includes such features as shape, colour, border, contour, evidence of surface crusting or ulceration and its proximity to the primary lesion and the resection margins)

G2.08 *Block identification key

G2.09 Other comments

Microscopic findings

G3.01 Microscopic description

S3.01 *__Breslow thickness__

(Measurement should be to a minimum of 1 decimal point and to a degree of precision as to allow accurate AJCC staging)

Specify ◯ ▶ At least ◯ ▶ mm Indeterminate ◯

S3.02 *__SURGICAL MARGIN/TISSUE EDGES STATUS__

*__In situ component: Peripheral margin__

Cannot be assessed ◯
Not involved by melanoma in situ ◯ ▼

mm *Distance of melanoma in situ from closest margin

*Specify location(s) of closest uninvolved margin if possible

Involved by melanoma in situ ◯ ▼

*Specify location(s), involved margins if possible

*__Invasive component: Peripheral margin__

Cannot be assessed ◯
Not involved by invasive melanoma ◯ ▼

mm *Dist. of invasive melanoma from closest peripheral margin

*Specify location(s) of closest uninvolved margin if possible

Involved by invasive melanoma ◯ ▼

*Specify location(s), involved margins if possible

*__Invasive component: Deep margin__

Cannot be assessed ◯
Not involved by invasive melanoma ◯ ▼

mm *Distance of invasive melanoma from margin

*Specify location(s) of closest uninvolved margin if possible

Involved by invasive melanoma ◯ ▼

*Specify location(s), involved margins if possible

S3.03 *__Ulceration__

Indeterminate ◯
Not identified ◯ Present ◯ ▼

G3.02 *Extent of ulceration mm

S3.04 *__Mitotic count__ mm^2

S3.05 *__Satellites__

Indeterminate ◯
Not identified ◯ Present ◯ ▼

*__Satellites: margins__

◯ Cannot be assessed
◯ Not involved by satellite
◯ Involved by satellite

G3.03 *Clark level

◯ Confined to epidermis (I)
◯ Infiltrates but does not fill papillary dermis (II)
◯ Fills/expands papillary dermis(III)
◯ Infiltrates into reticular dermis (IV)
◯ Infiltrates into subcutaneous fat (V)

S3.06 *__Lymphovascular invasion__

Indeterminate ◯
Not identified ◯ Present ◯

G3.04 *Tumour-infiltrating lymphocytes (early regression)

Not identified ◯
Non-brisk ◯ Brisk ◯

G3.05 *Tumour regression (intermediate and late)

Indeterminate ◯
Not identified ◯ Present ◯ ▼

Extent of regression

width mm x depth mm

G3.06 *Tumour regression (intermediate and late): margins

- ◯ Cannot be assessed
- ◯ Involved by regression
- ◯ Not involved by regression

Clearance from margins of excision

mm

S3.07 ***Desmoplastic melanoma component**

Not identified ◯
Present ◯

***Pure/Mixed**

- ◯ Pure desmoplastic melanoma (>90% desmoplastic features)
- ◯ Mixed (mixed desmoplastic / non-desmoplastic melanoma)

S3.08 ***Neurotropism**

Indeterminate ◯
Not identified ◯ Present ◯

G3.07 *Associated melanocytic lesion

Not identified ◯
Present ◯

G3.08 Intraepidermal melanoma growth pattern

- ◯ Pagetoid
- ◯ Lentiginous
- ◯ Mixed pattern

G3.09 *Melanoma subtype
(1 or more maybe applicable) (Value list modified from the WHO Classification of Tumours. Pathology and Genetics of Skin Tumours. (2005).)

- ☐ Superficial spreading melanoma
- ☐ Nodular melanoma
- ☐ Lentigo maligna melanoma
- ☐ Acral-lentiginous melanoma
- ☐ Desmoplastic melanoma
- ☐ Melanoma arising from blue naevus
- ☐ Melanoma arising in giant congenital naevus
- ☐ Melanoma of childhood
- ☐ Naevoid melanoma
- ☐ Persistent melanoma
- ☐ Melanoma, not otherwise classified
- ☐ Other (specify)

S3.09 ***LYMPH NODE STATUS**
(If lymph nodes are not received these elements should NOT be reported.)

***No. of sentinel nodes examined**

***No. of positive sentinel nodes**

***Total number of nodes examined (sentinel and non-sentinel)**

***Total number of positive nodes examined (sentinel and non-sentinel)**

G3.10 *Sentinel lymph node metastasis: location of tumour within the lymph node

- ◯ Subcapsular
- ◯ Intraparenchymal
- ◯ Both subcapsular and intraparenchymal

*Sentinel lymph node metastasis: extranodal extension

- ◯ Not identified
- ◯ Present
- ◯ Indeterminate

*Sentinel lymph node metastasis: maximum single dimension of the largest discrete metastasis

mm

G3.11 Additional comment

Synthesis and overview

S5.01 ***PATHOLOGICAL STAGING (AJCC 7TH Ed) Primary tumour (T)** (Refer p 5)

S5.02 ***PATHOLOGICAL STAGING (AJCC 7TH Ed) Regional lymph nodes (N)**

◯ No nodes submitted or found
OR

(Refer p 5)

S5.03 Year of publication and edition of staging system

G5.01 Diagnostic summary

specimen type, tumour site and laterality, tumour type, tumour pTpN stage, involvement of specimen margins

S5.04 Overarching comment

PATHOLOGICAL STAGING (AJCC 7TH Ed)##

T classification

TX Primary Tumour cannot be assessed
T0 No evidence of primary tumour
Tis Melanoma in situ
T1 Melanomas ≤1.0 mm in thickness
T1a Without ulceration and mitosis <1/mm2
T1b With ulceration or mitoses ≥ 1/mm2
T2 Melanomas 1.01–2.0 mm
T2a without ulceration
T2b with ulceration
T3 Melanomas 2.01–4.0 mm
T3a without ulceration
T3b with ulceration
T4 Melanomas >4.0 mm
T4a without ulceration
T4b with ulceration

N classification

NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 1 node
N1a micrometastasis*
N1b macrometastasis**
N2 2–3 nodes
N2a micrometastasis*
N2b macrometastasis**
N2c in transit met(s)/satellite(s) without metastatic nodes
N3 4 or more metastatic nodes, or matted nodes, or in transit met(s)/ satellite(s) with metastatic node(s)

* Micrometastases are diagnosed after sentinel lymph node biopsy and completion lymphadenectomy (if performed).

** Macrometastases are defined as clinically detectable nodal metastases confirmed by therapeutic lymphadenectomy or when nodal metastasis exhibits gross extracapsular extension.

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science and Business Media LLC, www.springerlink.com.